Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor
Copyright 2000 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2000
In Reply: We agree with Dr Gagnon that it is
only rational for pharmaceutical firms to support positive economic analyses,
although that does not preclude conflict of interest. It should also be noted
that the perspective of our study is from the scientific community, not from
the pharmaceutical industry. We found that fewer studies with negative results
are sponsored by pharmaceutical firms, which leads to a bias in the available
economic literature for these drugs. As Dr Le Pen notes, pharmacoeconomic
research (and medical research in general) would benefit from the publication
of studies with both positive and negative results.
Friedberg M, Saffran B, Stinson T, Bennett C. Sources of Bias in the Economic Analysis of New Drugs—Reply. JAMA. 2000;283(11):1423-1424. doi:10.1001/jama.283.11.1421